Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Alector, Inc.

We have always walked our own path, at Alector. That’s what led us to the bold thinking and fresh, new approach of empowering the body’s immune system to fight disease. 

Join us in our mission to eliminate neurodegeneration and cancer through immuno-neurology and immuno-oncology. We are developing a broad portfolio of programs, currently in various stages of clinical trials. 

Alector is based in South San Francisco, CA. We were founded in 2013 by thought leaders in biotechnology, neuroscience, and antibody drug discovery.

INmuneBIO

OrbiMed

Polaris Partners

Mission Bay Capital

Section 32 Mission BioCapital

Casdin Capital

Google Ventures

Deerfield Capital Management

Euclidean Capital

Amgen Ventures

Alector

2023 was an exceptional year for Alector. Patients & their families were at the forefront of our minds as we executed on our mission and moved closer to achieving our ambitious vision of making brain disorders history. Below, Alector leaders Arnon Rosenthal and Sara Kenkare-Mitra share their reflections on this year as we head into #2024.

Last week, Alector hosted two R&D webinars for analysts, investors & industry on our targets TREM2 and PGRN and shared the significant progress we have made across our clinical programs. We were joined by esteemed thought leaders in the field who contributed to an invaluable dialog. You can catch up on the conversation at the link below. 

Alector continues to be a pioneer in immuno-neurology, and we are excited about the potential to make a difference in the lives of people with #neurodegenerative diseases. 

https://lnkd.in/eARBjk6

During this season of gratitude, we're reminded how lucky we are to have the opportunity to #giveback to our local community. We partnered with Family Giving Tree once again this holiday season to collect gifts and funds for local families in need. We're inspired by the incredibly valuable work organizations like these do. 🎁

The holidays offer a unique opportunity to remind loved ones how much we care about them through gifts or quality time. Taking care of our brain health becomes increasingly important as we grow older. Check out Alector’s top 6 evidence-based holiday gift ideas for enhancing cognitive reserve and lowering risk of #dementia.

Sources: https://lnkd.in/es7R7PAD

The commitment to advocating for, and caring for, people living with a #neurodegenerative disease does not stop, regardless of the season. This winter, we continue to be in awe of our advocacy group partners and their dedication to patients and their families. Thank you for all you do.

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-15.11M -	-32.48M 114.96%	-52.25M 60.86%	-105.39M 101.70%	-190.23M 80.51%	-36.33M 80.90%	-133.31M 266.95%	-130.39M 2.19%
depreciation and amortization	201K -	680K 238.31%	1.02M 49.85%	5.57M 447.01%	7.26M 30.34%	8.31M 14.45%	8.47M 1.89%	8.85M 4.44%
deferred income tax								377K -
stock based compensation	1.96M -	5.35M 172.75%	6.92M 29.34%	16.28M 135.10%	30.52M 87.47%	40.78M 33.62%	46.15M 13.14%	42.80M 7.26%
change in working capital	-47K -	8.68M 18,557.45%	174.36M 1,909.94%	-12.27M 107.04%	-15.22M 24.02%	283.68M 1,963.63%	59.53M 79.02%	-90.15M 251.44%
accounts receivables	-218K -	-20K 90.83%	238K 1,290%			-7.39M -	4.80M 165.00%	2.59M 46.15%
inventory	-560K -	6.58M 1,275%	2.45M 62.80%			7.39M -	-4.80M 165.00%	-2.59M 46.15%
accounts payables	708K -	-41K 105.79%	-809K 1,873.17%	152K 118.79%	2.41M 1,484.87%	1.92M 20.42%	-572K 129.84%	-377K 34.09%
other working capital	23K -	2.16M 9,273.91%	172.49M 7,900.23%	-12.43M 107.20%	-17.63M 41.89%	281.76M 1,698.12%	60.10M 78.67%	-89.77M 249.37%
other non cash items			-2.59M -	-3.50M 35.08%	929K 126.51%	2.10M 125.94%	-1.16M 155.41%	-15.65M 1,245.40%
net cash provided by operating activities	-12.99M -	-17.77M 36.77%	127.46M 817.26%	-99.31M 177.91%	-166.73M 67.90%	298.55M 279.06%	-20.33M 106.81%	-184.16M 805.91%
investments in property plant and equipment	-2.25M -	-801K 64.40%	-1.88M 135.21%	-15.27M 710.24%	-5.03M 67.04%	-3.25M 35.47%	-4.12M 26.79%	-2.38M 42.17%
acquisitions net				33.61M -	100.02M 197.60%	49.66M 50.35%	159.01M 220.19%
purchases of investments			-472.24M -	-529.61M 12.15%	-506.81M 4.31%	-343.40M 32.24%	-556.90M 62.17%	-551.73M 0.93%
sales maturities of investments			250M -	496M 98.40%	406.79M 17.99%	296.99M 26.99%	402.00M 35.36%	656.03M 63.19%
other investing activites				-33.61M -	-100.02M 197.60%	-49.66M 50.35%	-159.01M 220.19%
net cash used for investing activites	-2.25M -	-801K 64.40%	-224.12M 27,879.90%	-48.87M 78.19%	-105.05M 114.94%	-49.66M 52.72%	-159.01M 220.19%	101.92M 164.09%
debt repayment				-868K -	-2.41M 177.30%	-4.01M 66.68%	-4.27M 6.53%
common stock issued			133.05M -	170.13M 27.87%	224.60M 32.02%	30.30M 86.51%	3.06M 89.90%	1.47M 51.91%
common stock repurchased	-77K -	-15K 80.52%	-1.90M 12,593.33%
dividends paid
other financing activites				3.09M -	9.92M 220.63%	4.01M 59.54%	5.73M 42.80%	1.08M 81.17%
net cash used provided by financing activities	-77K -	-15K 80.52%	131.15M 874,406.67%	172.35M 31.42%	232.11M 34.67%	30.30M 86.95%	4.51M 85.10%	2.55M 43.51%
effect of forex changes on cash
net change in cash	-15.32M -	-18.59M 21.33%	34.49M 285.57%	24.17M 29.92%	-39.67M 264.13%	279.18M 803.73%	-174.83M 162.62%	-79.69M 54.42%
cash at beginning of period	66.36M -	51.04M 23.09%	32.45M 36.42%	66.94M 106.29%	91.11M 36.11%	51.44M 43.54%	330.62M 542.72%	155.79M 52.88%
cash at end of period	51.04M -	32.45M 36.42%	66.94M 106.29%	91.11M 36.11%	51.44M 43.54%	330.62M 542.72%	155.79M 52.88%	76.10M 51.15%
operating cash flow	-12.99M -	-17.77M 36.77%	127.46M 817.26%	-99.31M 177.91%	-166.73M 67.90%	298.55M 279.06%	-20.33M 106.81%	-184.16M 805.91%
capital expenditure	-2.25M -	-801K 64.40%	-1.88M 135.21%	-15.27M 710.24%	-5.03M 67.04%	-3.25M 35.47%	-4.12M 26.79%	-2.38M 42.17%
free cash flow	-15.24M -	-18.57M 21.84%	125.58M 776.18%	-114.57M 191.24%	-171.77M 49.92%	295.30M 271.92%	-24.45M 108.28%	-186.54M 663.08%

COM:ALECTOR

Alector, Inc.

Last Close

3.76

22/11 21:00

Market Cap

483.85M

Beta: -

Volume Today

715.70K

Avg: -

Preview